Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951314 | 0.93 | HRH3 (0.64) | HRH3ROCK2CYP3A4SYKPIN1 | |
| SCHEMBL2952603 | 0.87 | HRH3 (0.83) | HRH3SYKMEN1KMT2A | |
| SCHEMBL2947010 | 0.86 | HRH3 (0.82) | HRH3SYKMEN1KMT2A | |
| SCHEMBL2951205 | 0.86 | HRH3 (0.67) | HRH3ROCK2CYP3A4SYKMEN1 | |
| SCHEMBL2952638 | 0.86 | HRH3 (0.67) | HRH3ROCK2CYP3A4SYKMEN1 | |
| SCHEMBL2943709 | 0.85 | HRH3 (0.66) | HRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL2952637 | 0.85 | HRH3 (0.66) | HRH3ROCK2CYP3A4SYKMEN1 | |
| SCHEMBL2947472 | 0.84 | HRH3 (1.00) | HRH3SYK | |
| SCHEMBL2943726 | 0.84 | HRH3 (0.79) | HRH3SYKMEN1KMT2A | |
| SCHEMBL2952598 | 0.84 | HRH3 (0.53) | HRH3ROCK2CYP3A4SYKPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-01 | — | — | US | claimed |
| EP-2909190-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | claimed |
| WO-2014060386-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | claimed |
| EP-1841734-B1 | 5-AMINOINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | claimed |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2909190-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060386-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| EP-2722329-A1 | Indol-amide compounds as beta-amyloid inhbitors | F. Hoffmann-La Roche AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| US-7754736-B2 | 5-aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1841734-B1 | 5-AMINOINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20090069311-A1 | 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS | NETTEKOVEN MATTHIAS HEINRICH | 2009-03-12 | — | — | US | disclosed |
| US-7456174-B2 | 5-aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1841734-A2 | 5-AMINOINDOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077024-A2 | 5-AMINOINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160855-A1 | 5-Aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069311-A1 | 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS | HRH3, HTR5A, HRH4 | HRH3 1/4885ROCK2 1560/4885CYP3A4 824/4885 |
| US-20060160855-A1 | 5-Aminoindole derivatives as H3 inverse agonists | HRH3, HTR5A, HRH4 | HRH3 1/4885ROCK2 1560/4885CYP3A4 824/4885 |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | APP, BACE1, IAPP | HRH3 259/4885ROCK2 1605/4885CYP3A4 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.